Andrew D Zelenetz MD PhD

PubMed

• Two decades of single-institution data reveal rare longterm survivors of relapsed/refractory Burkitt lymphoma.
  Rabeya Molla, Kurt Bantilan, Ellin Berman, Philip Caron, Lorenzo Falchi
  Haematologica. 2026-01-01
• CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.
  Joseph M Rocco, Joseph H Oved, Rikita J Patel, A Zara Herskovits, Namitha Nair
  Blood. 2025-12-10
• Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.
  Nirav N Shah, Pier Luigi Zinzani, Michael Wang, Sunita D Nasta, Ewa Lech-Maranda
  Blood Advances. 2025-12-09

Journal Articles

• Venetoclax plus R- or G-CHOP in Non-Hodgkin Lymphoma: Results from the CAVALLI Phase 1b Trial  
  Andrew D Zelenetz, Andre Goy, Mehrdad Mobasher, Carla Casulo, Blood
• Clonal Diversity Predicts Adverse Outcome in Chronic Lymphocytic Leukemia  
  Tariq Mughal, Nicole Lamanna, Andrew Zelenetz, Mark G Frattini, Nature
• Real World Outcomes and Management Strategies for Venetoclax-Treated Chronic Lymphocytic Leukemia Patients in the United States  
  Arun K Singavi, Andrew Zelenetz, Nicole Lamanna, Bruce D Cheson, Richard R Furman, Jakub Svoboda, Stephen J Schuster, John N Allan, Chaitra S Ujjani, Haematologica

Books/Book Chapters

• Methods of Enzymology. 
  Chapter: Efficient construction of complex directional cDNA libraries in a SfiI cassette 
  Page 517 - 530Zelenetz ADEditors: Wu R.Academic Press Inc, San Diego, CA
• The Non-Hodgkin’s Lymphomas. 
  Chapter: The pathogenesis of the low grade B-cell lymphomas 
  Zelenetz AD, Brodeur DEditors: Magrath, I.Edward Arnold, Kent, United KingdomEdition 2,
• Oncology. 
  Chapter: The non-Hodgkin’s Lymphomas – An Evidence Based Approach 
  Zelenetz, A.D., Horwitz S.MEditors: Chang, A.E., Ganz P.A., Hayes, D.F., Kinsella T., Pass, H.I., Schiller, J.H., Stone, R.M., Strecher.

Abstracts/Posters

• Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
  Andrew D. Zelenetz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL...
  Andrew D. Zelenetz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL...
  Andrew D. Zelenetz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• Results of the PI3Kδ inhibitor ME-401 alone or with rituximab in relapsed/refractory (R/R) follicular lymphoma (FL). 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
• 17th International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas and Myeloma® 
  Physicians' Education Resource, LLC, New York, New York - 2/15/2013